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Behavioral Determinants of Successful Early
Melanoma Detection
Role of Self and Physician Skin Examination
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BACKGROUND. Reduced melanoma mortality should result from an improved understanding of modifiable factors
related to early detection. The authors of this report surveyed newly diagnosed patients to identify differences in pre-
diagnosis behavioral and medical care factors associated with thinner versus thicker melanoma. METHODS. In total,
566 adults with invasive melanoma completed questionnaires within 3 months of diagnosis on demographics, health
care access, skin self-examination (SSE), and physician skin examination (PSE) practices in the year before diagnosis.
SSE was measured by use of a melanoma picture aid and routine examination of some/all body sites versus none.
Patient-reported partial or full-body PSE also was assessed. Melanoma thickness was dichotomized at 1 mm.
RESULTS. Patients ranged in age from 18 years to 99 years, and 61% were men. The median tumor thickness was 1.25
mm, and 321 tumors (57%) were >1 mm thick. Thinner tumors (1 mm) were associated with age 60 years (P ¼
.0002), women (P ¼ .0127), higher education level (P ¼ .0122), and physician discovery (P  .0001). Patients who
used a melanoma picture aid and performed routine SSE were more likely to have thinner tumors than those who did
not (odds ratio [OR], 2.66; 95% confidence interval [CI], 1.48-4.80). Full-body PSE was associated with thinner
tumors (OR, 2.51; 95% CI, 1.62-3.87), largely because of the effect of PSE in men aged >60 years (OR, 4.09 95% CI,
1.88-8.89). CONCLUSIONS. SSE and PSE were identified as complementary early detection strategies, particularly
in men aged >60 years, in whom both partial and full-body PSE were associated with thinner tumors. Given the high
rates of physician access, PSE may be a more practical approach for successful early detection in this subgroup with
highest mortality. Cancer 2012;118:3725-34. VC 2011 American Cancer Society.
KEYWORDS: melanoma, early detection of cancer, prevention and control, self-examination, screening.
INTRODUCTION
Known factors related to thinner versus thicker cutaneous melanomas at diagnosis involve characteristics related to the
patient, tumor, and mode of discovery. Thinner tumors are associated with physician detection (vs detection by the
patient or significant other),1-9 women,1,4,6,10-14 younger age,10-15 higher level of education6,8,14-16 and socioeconomic
status,17-20 increased access to specialty care,2,5,6,9,21 presence of atypical nevi,4,8 and non-nodular or desmoplastic histo-
logic subtypes.10-13,22-25 However, these factors have not been studied in combination with patient health behaviors and
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practices (eg, skin self-examination [SSE] and health care
use) and physician skin examination (PSE) during routine
medical care, as a means to promote early detection of
cutaneous melanoma.
We performed a multi-institutional assessment of
prediagnosis behavioral and medical care/access factors in
men and women aged 18 years with newly diagnosed,
cutaneous melanoma to identify differences associated
with thinner versus thicker tumors. Our objective was to
investigate the associations among self- and physician ex-
amination practices and thinner melanoma at diagnosis,
to more effectively formulate clinical and public health
strategies for early melanoma detection. We hypothesized
that both PSE and SSE practices would result in the diag-
nosis of thinner tumors; that their effect would differ
according to age, sex, and type of skin examination per-
formed (full-body vs partial); and that regular health care




Approval for the study was obtained from the institu-
tional review boards of Stanford University Medical
Center (SUMC), Veterans Affairs Palo Alto Health
Care System (VAPAHCS), and the University of Michi-
gan (UM). Eligible, consecutive patients aged 18 years
with a recent diagnosis of invasive cutaneous melanoma
were surveyed at SUMC/VAPAHCS, as previously
described.26 Because of the high proportion of thin
melanoma at UM, which evaluates a population-based
sample representative of the state (concordant with the
state registrar), all eligible patients with melanoma
>2 mm and a random sample of 33% of individuals
with tumors 2 mm were surveyed. Patients were sur-
veyed in the melanoma clinics from May 17, 2006
through March 31, 2009, within 3 months of diagnos-
tic biopsy. Respondents were instructed in person to an-
swer all questions for the 12 months before diagnosis,
and there were reminders in multiple locations on the
survey to reinforce this point.
Skin Self-Examination Measures
We used a previously published measurement of SSE
incorporating the number of body sites examined (rang-
ing from 1 to 13 sites) and the use of a picture aid illustrat-
ing a melanoma tumor.26 An earlier analysis of a subset of
our study patients (321 of 566) that examined only the
effect of SSE had demonstrated that routine inspection
of at least some of the measured body areas and use of a
melanoma picture aid were associated significantly with
reduced tumor thickness, whereas the frequency of mole
examination was not.
Demographic Measures
The data analyzed included patient demographics (age,
sex, education level, race/ethnicity, marital/cohabitation
status), previous melanoma and nonmelanoma skin
cancer history, and family history of skin cancer. Nevus
count and the presence of clinical atypical nevi (CAN)
were assessed by the clinician at the initial melanoma visit.
Age was dichotomized at age 60 years given increasing
rates of thicker tumors and increased mortality among
older individuals (especially men)20,27-29 and evidence
suggesting differences in melanoma awareness and skin
examination practices by age.10-15
Physician Skin Examination Variables
Health care use in the year before diagnosis was assessed
by questions asking where patients usually went when sick
or in need of health advice (physician’s office/clinic/health
center vs urgent care center/emergency room vs other),
whether they had a physician whom they consulted regu-
larly for routine care, howmany times they visited a physi-
cian during this year, whether a physician examined their
skin for cancer during any visits, and whether the physi-
cian examined the patient’s whole skin or just a particular
lesion. Patients who responded ‘‘do not know’’ were
excluded from specific analyses.
Outcome Measures
The primary study outcome was melanoma tumor depth
at diagnosis. Because nearly 75% of fatal melanomas are
associated with lesions thicker than 1 mm,30 this tumor
cutoff point was used. We considered analyzing tumor
thickness as a continuous outcome variable; however, this
required log transformation to correct for the right-
skewed distribution of melanoma thickness and the pre-
sentation of data with a geometric mean thickness,26
which are not easily interpretable.
Statistical Analysis
We used chi-square statistics to assess associations and
conducted multivariable logistic regression analyses to
assess the effects of various patient characteristics on mela-
noma tumor thickness at diagnosis. The odds ratio (OR)
and 95% confidence interval (CI) for having a thinner
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(1 mm thick) tumor was calculated for different levels
of each patient measure compared with a reference level.
Decisions to include covariates as confounders in the
models were based on a 10% change in the size of the
independent variable’s beta parameter upon inclusion of
the covariate. The potential confounders examined
included age, sex, race/ethnicity, education level, nevus
count, and histologic subtype. Age, sex, and nevus count
were retained in the models.
Statistical interaction between SSE measures and
covariates was assessed by the significance of interaction
terms (cutoff of P < .2 for consideration) that were
entered into the models, and likelihood ratio tests were
used to compare the model fit.31 Age, sex, education, his-
tology, and the number of physician visits in the last year
were examined as potential effect modifiers. Analyses
were conducted using the SAS statistical software package
(version 9.2; SAS Institute, Inc., Cary, NC). All tests of




In total, 566 of 719 eligible patients completed the ques-
tionnaire (79%), including 225 from SUMC/VAPAHCS
and 341 from UM. Refusals were related to patients’ lack
of interest/time, visual impairment, or anxiety related to
diagnosis. Table 1 presents patient demographic informa-
tion and tumor characteristics. Patients ranged in age
from 18 years to 99 years (mean  standard deviation,
56.4 15.8 years; median, 58 years). Ninety-four percent
of patients reported this as their first melanoma, and 95%
denied having a prior nonmelanoma skin cancer.
Tumor Characteristics
The median tumor thickness was 1.25 mm (mean 
standard deviation, 2.14  2.64 mm), and 321 patients
(57%) had melanomas>1 mm thick. The median tumor
thickness for patients from SUMC/VAPAHCS and from
UM was 1.2 mm and 1.3 mm, respectively. Frequencies
according to the American Joint Committee on Cancer
2009 tumor classification32 were 43% T1, 23% T2, 21%
T3, and 13% T4. Thinner tumors were associated with
superficial spreading (P < .0001) and lentigo maligna (P
¼ .012) histologic subtypes and with visible tumor pig-
mentation (vs amelanotic; P ¼ .0002), absence of ulcera-
tion (P  .0001), and extremity or trunk location
compared with head and neck location (P .0001).
Patient Characteristics
Thinner tumors were associated with younger age (60
years; P< .0001), women (P¼ .0127), and a higher edu-
cation level (P¼ .0122) but not with marital/cohabitation
status, prior skin cancer, or personal or family history of
skin cancer. Thinner tumors were not associated with the
presence of CAN, which was evident in 26% of respond-
ents (OR, 1.06; 95% CI, 0.65-1.72), or with an increas-
ing number of moles (OR, 1.60; 95% CI, 0.88-2.92
for patients with >50 moles vs 50 moles). However,
thinner tumors were associated with the patient previously
being told by a physician that he/she had atypical/dysplas-
tic nevi (OR, 1.88; 95%CI, 1.15-3.06).
Mode of Melanoma Discovery
Most patients (53%) self-detected melanoma compared
with detection by physicians (19%), spouse/partners
(16%), and family members/friends/other (11%). Der-
matologists detected 74 melanomas (13%) compared
with 35 melanomas (6%) that were detected by primary
care physicians. Self-detection was more common in
younger patients (aged 60 years) than in older patients
(57% vs 46%; P ¼ .01). Tumors discovered by a physi-
cian were significantly thinner than those discovered by
the spouse/partner or by the patient (OR, 4.98; 95% CI,
3.00-8.27 for physician detection vs patient detection).
No significant difference was observed between discovery
by a dermatologist (median thickness, 0.73 mm) versus a
nondermatologist (0.72 mm). There was no clear pattern
of association between how long patients waited to see a
physician for a skin examination after noting a suspicious
skin lesion and thickness.
Skin Self-Examination Practices
and Thickness
Twenty-four percent of patients reported use of a mela-
noma picture for SSE in the year before diagnosis, the use
of which was associated with thinner tumors, as was rou-
tine self-examination of some/all of the body compared
with none (OR, 1.98; 95% CI, 1.24-3.18) (Table 2). The
use of a melanoma picture aid in combination with rou-
tine SSE had an even stronger association with thinner
tumors (OR, 2.66; 95% CI, 1.48-4.80) compared with
neither of these practices.
Medical Access, Health Care Use, and
Physician Skin Examination
Greater than 95% of patients had health insurance, and
82% had a regular physician. Eighty-nine percent of
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patients reported at least 1 physician visit in the year
before diagnosis, and 47% reported receiving a skin exam-
ination. Thinner tumors were associated with having 1) a
regular health care location/facility when sick/needing
advice (OR, 1.64; 95% CI, 0.95-2.84), 2) a physician for
routine care (OR, 1.64; 95% CI, 1.03-2.62), 3) at least 1
physician visit (OR, 3.62; 95% CI, 1.75-7.48), and 4)
receiving a PSE for cancer (OR, 1.78; 95%CI, 1.24-2.56)
(Table 3). Overall, patients who received a full-body skin
examination were significantly more likely to have thinner
tumors (OR, 2.51; 95% CI 1.62-3.87), whereas those
who only had a particular lesion examined were not.
Effect Modification by Age and by Sex
A strong statistical interaction was observed by age (dicho-
tomized at age 60 years) and sex for the associations
between multiple measures of PSE and SSE and tumor
thickness (Table 4). Patients aged >60 years who had a
Table 1. Frequencies of Sociodemographic Variables, Tumor Characteristics, and Nevus Count by
Melanoma Tumor Depth at Diagnosis Dichotomized at 1 Millimeter Thickness (N ¼ 566
Tumor Depth Dicho-
tomized at 1 mm:
Frequency (%)
Variable £1 mm >1 mm Row Total P
Age, y .0002
£40 55 (54) 46 (46) 101
41-50 48 (47) 54 (53) 102
51-60 67 (50) 67 (50) 134
61-70 46 (39) 72 (61) 118
‡71 29 (26) 82 (74) 111
Sex .0127
Men 135 (39) 210 (61) 345
Women 110 (50) 111 (50) 221
Education .0122
High school 71 (36) 127 (64) 198
Associates’ degree 40 (41) 57 (59) 97
Four-year college 134 (49) 137 (51) 271
Race/ethnicity .1422
White 237 (44) 302 (56) 539
Nonwhite 8 (30) 19 (70) 27
No. of nevi .1590
0-20 156 (42) 218 (58) 374
20-50 47 (41) 69 (59) 116
50-100 31 (55) 25 (45) 56
‡100 11 (55) 9 (45) 20
Histologic subtype <.0001
SSM 188 (58) 135 (42) 323
NOD 3 (4) 78 (96) 81
LMM 29 (60) 19 (40) 48
ALM 5 (28) 13 (72) 18
Desmoplastic 2 (9) 21 (91) 23
Other/unclassified 16 (24) 51 (76) 67
Ulceration <.0001
Yes 5 (5) 104 (95) 109
No 239 (53) 210 (47) 449
Anatomic location <.0001
Head/neck 32 (26) 91 (74) 123
Trunk 100 (48) 109 (52) 209
Extremity 105 (49) 111 (51) 216
Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NOD, nodular melanoma; SSM, su-
perficial spreading melanoma.
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physician examine their skin for cancer had signifi-
cantly higher odds of having a thinner tumor (OR,
3.11; 95% CI, 1.65-5.86) compared with those who
did not. In contrast, receipt of a PSE was not associ-
ated with thinner tumors among patients aged <60
years. Patients aged >60 years who received a full-body
or partial PSE were more likely to have thinner tumors
compared with those who did not (OR, 3.67 [95% CI,
1.84-7.33] and OR, 2.93 [95% CI, 1.29-6.67], respec-
tively). Receipt of a full-body PSE was associated
with thinner tumors (OR, 2.06; 95% CI, 1.14-3.71)
among younger patients, but receipt of a partial PSE
was not.
The associations between PSE and thinner tumors
also were much stronger among men who received a PSE
for skin cancer, particularly a full-body PSE (OR, 3.13;
95% CI, 1.82-5.39) versus a partial PSE (OR, 1.28; 95%
CI, 0.67-2.42), and among men who had a regular physi-
cian (OR, 2.58; 95% CI, 1.35-4.94). Women demon-
strated no significant differences in the odds of having a
thinner tumor by these variables.
Age and sex also had a strong interaction with 1
measure of SSE. Among patients aged >60 years, those
who had used a melanoma picture to aid in SSE were
more likely to have thinner tumors than those who did
not (OR, 2.84; 95%CI, 1.46-5.49). Among patients aged
60 years, however, use of a melanoma picture aid and
tumor thickness were unrelated. Men who had used a pic-
ture aid were more likely to have thinner tumors (OR,
1.88; 95% CI, 1.12-3.16), but no effect was observed
among women. Age and sex were not strong effect modi-
fiers of the association between the other SSE variables
and tumor thickness. An assessment of interaction
between age, sex, and certain variables (such as whether
patients had consulted a physician in the last year) was not
possible given sample size limitations.
Table 2. Frequencies of Patient-Associated Behaviors/Practices Related to Skin Self-Examination With Odds Ratios and 95%






Ever used a melanoma picture to aid in SSEa
Yes 134 1.43 0.96-2.14
No 415 Ref
How often patient carefully examined his/her molesa
Every 1-2 mo 102 0.79 0.49-1.27
Every 6 m 94 1.18 0.72-1.93
Every y 94 1.00 0.61-1.64
Never 258 Ref
Routinely examined skin on some/all of bodya
Some/all 465 1.98 1.24-3.18
None 101 Ref
Routinely examined skin and/or ever used a picture aid in SSEa
No picture aid but routinely examined some/all of skin 326 2.17 1.28-3.66
Used picture aid for routine SSE 134 2.66 1.48-4.80
No picture aid, did not routinely examine skin 89 Ref
When patient first became concerned about the skin lesion
Only at time of diagnosis 171 1.91 0.97-3.77
£1 y 340 0.65 0.35-1.23
>1 y before diagnosis 47 Ref
Could easily see the lesion
Yes 362 0.67 0.46-0.97
No/do not know 181 Ref
Lesion color
Do not know 62 1.29 0.73-2.27
Pink 76 0.44 0.25-0.76
Skin colored 32 0.22 0.08-0.58
Pigmented 368 Ref
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference group; SSE, skin self-examination.
a SSE variables pertain to the year before melanoma diagnosis.
Determinants of Early Melanoma Detection/Swetter et al
Cancer August 1, 2012 3729
Simultaneous Effect Modification
by Age and Sex
The presence of simultaneous effect modification by age and
sex required stratifying the associations between the 3 varia-
bles addressed above and tumor thickness into 4 age/sex
groups (Table 4). Among men aged >60 years, thinner
tumors were strongly associated with having received a PSE
for cancer (OR, 4.09; 95% CI, 1.88-8.89). No significant
associations between these variables and tumor depth were
observed in younger men or in women of any age. These
findings persisted when analyzed by histologic subtype and
by the number of physician visits in the year before diagnosis.
DISCUSSION
Disproportionate melanoma incidence and mortality
have been demonstrated in middle-aged and older men
worldwide.20,27,28,33 Compared with other demographic
groups, older men tend to have thicker, more fatal mela-
nomas10,13,15; more nodular melanoma11,22; and partici-
pate less frequently in mass screening efforts34 or in
deliberate SSE.35 Our study demonstrated that thinner
tumors in men aged >60 years were strongly associated
with PSE, and this result supports the rigorous education
of physicians regarding the benefits of full-body skin
examination during routine care and of older men regard-
ing the value of routine SSE and at least annual PSE.
Our results verify known associations with thinner
melanoma at diagnosis, including younger age, female gen-
der, location on anatomic sites other than the head or neck,
patient perception of having CAN (as opposed to clinician
assessment), higher educational level, visible tumor pigmen-
tation, non-nodular or desmoplastic histologic subtype, and
physician detection. More important, these results demon-
strate the detection of thinner tumors in patients who, in
the year before diagnosis, 1) regularly examined their own
skin, 2) consulted a physician at least once, and 3) received
full-body PSE for cancer, although examination of even a
Table 3. Frequencies of Health Care-Associated Behaviors/Practices With Odds Ratios and 95% Confidence Intervals That the






Had a usual place to go when sick/needed health advicea
Other 69 Ref
Physician’s office/clinic/health left 488 1.64 0.95-2.84
Had a physician for routine carea
No 102 Ref
Yes 455 1.64 1.03-2.62
Patient states they received a physician skin examination for cancera
No 289 Ref
Yes 258 1.78 1.24-2.56
Type of skin examination performed by physician
None 289 Ref
Particular lesion 93 1.16 0.71-1.90
Whole skin 147 2.51 1.62-3.87
Who first noticed the mark that turned out to be melanoma?
You 189 Ref
Primary care physician/dermatologist 109 4.98 3.00-8.27
Spouse/family/friend 78 1.32 0.85-2.05
During the year before you found out you had melanoma, how many times did you visit a physician?
None 48 Ref
Once 131 3.18 1.46-6.95
2-3 Times 203 4.17 1.96-8.89
>3 Times 173 3.36 1.54-7.33
During the year before you found out you had melanoma, did you visit a physician at least once?
No 48 Ref
Yes 507 3.62 1.75-7.48
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference group.
a Variables pertain to the year before melanoma diagnosis.
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Table 4. Odds Ratios by Age and Sex: Frequencies of Variables With Odds Ratios and 95%
Confidence Intervals That the Patient Had a Thinner Tumor (1 mm) at Diagnosis, Adjusted for
Age and Stratified According to Age 60 Years Versus Age >60 Years, Sex, or Both Age and Sex
Variable/Subgroup Response No. of
Patients
OR for Tumor
£1 mm (95% CI)
Stratified by age
Ever used melanoma picture to look at skina
Aged £60 y
No 246 Ref
Yes 84 0.94 (0.57-1.57)
Aged >60 y
No 169 Ref
Yes 50 2.84 (1.46-5.49)
Patient states they received a physician skin examination for cancera
Aged £60 y
No 199 Ref
Yes 127 1.23 (0.79-1.99)
Aged >60 y
No 90 Ref
Yes 131 3.11 (1.65-5.86)
Type of skin examination performed by physician
Aged £60 y
None 199 Ref
Particular lesion 52 0.68 (0.36-1.28)
Whole skin 68 2.06 (1.14-3.71)
Aged >60 y
None 90 Ref
Particular lesion 41 2.93 (1.29-6.67)
Whole skin 79 3.67 (1.84-7.33)
Stratified by sex
Ever used melanoma picture to look at skina
Men
No 263 Ref
Yes 75 1.88 (1.12-3.16)
Women
No 152 Ref
Yes 59 1.00 (0.53-1.87)
Patient states they received a physician skin examination for cancera
Men
No 163 Ref
Yes 172 2.06 (1.29-3.28)
Women
No 126 Ref
Yes 86 1.37 (0.76-2.46)
Type of skin examination performed by physician
Men
None 163 Ref
Particular lesion/unsure 58 1.28 (0.67-2.42)
Whole skin 102 3.13 (1.82-5.39)
Women
None 126 Ref
Particular lesion/unsure 35 1.05 (0.48-2.32)
Whole skin 45 1.52 (0.74-3.12)
Stratified by age and sex
Patient states they received a physician skin examination for cancera
Men aged £60 y
No 104 Ref
Yes 72 1.27 (0.69-2.35)
Women aged £60 y
No 95 Ref
Yes 55 1.24 (0.62-2.49)
(Continued)
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particular lesion was beneficial for older adults. It is note-
worthy that the advantage of PSE was limited to men aged
>60 years, who had 4 times the odds of a thinner tumor
than older men who did not receive a PSE.
Middle-aged and older men comprise nearly half of
all melanoma deaths, but only 16% of US men in this
subgroup report ever receiving a physician screening.36,37
The importance of having regular access to medical care is
highlighted by the finding that 33% of study patients who
reported having a usual location for medical care and a
regular physician for routine care received full-body PSE
compared with only 11% of those who did not, although
more frequent visits did not increase the odds of having a
thinner tumor. SSE practices, as measured by the use of a
melanoma picture aid and routine examination of some
or all of the body, also significantly increased the odds of
having a thinner melanoma, although this effect was lim-
ited to men and to older patients.
The reasons for the lack of impact of SSE and PSE
on tumor thickness in men aged 60 years or in women
regardless of age are not clear, but different risks for mela-
noma and health surveillance behaviors/practices may
play a part. In general, older men have a higher risk of
developing melanoma and also participate less effectively
in their health matters than younger men and women.
Therefore, older men who undergo regular PSE may
receive the greatest benefit from this practice. Conversely,
physicians of older men may be more cognizant of the
higher incidence and mortality, less frequent SSE prac-
tices, and thicker histologic subtypes in this subgroup
and, thus, may perform PSEs more vigilantly. Younger
patients tend to self-detect melanoma more than older
patients14 (57% vs 46%, respectively, in our study), typi-
cally have thinner tumors, and may not require the same
frequency of PSE as older men.
The strongest evidence to date for the increased diag-
nosis of thinner tumors with physician skin screening was
reported in a population-based case-control study of
Queensland residents ages 20 to 75 years who had histologi-
cally confirmed, first primary, invasive melanoma.38 Whole-
body clinical skin examination by a physician 3 years before
diagnosis was associated with a 32% increased odds of hav-
ing a T1 (1 mm) melanoma at diagnosis. In addition, a
screening program that was initiated at the Lawrence Liver-
more National Laboratory and conducted between 1984
and 1996 demonstrated that increasedmelanoma education,
self-examination, and opportunity for PSE resulted in a
reduction in crude incidence of thickermelanomas, although
the study population was highly motivated.39 Whereas the
published data in support of the association of SSE on mela-
noma thickness26,40 are less robust than those in support of
PSE, our findings suggest that patient education and distri-
bution of picture aids to increase SSE practices are justified.
This is especially true among older men and is complemen-
tary to promoting PSE.
Our study inquired about PSE practices and health
care use in the year before diagnosis, and many questions
remain regarding why patients who had a PSE during that
time had thinner tumors than those who did not, espe-
cially because only 19% of melanomas were detected by
physicians. Without a proven survival benefit from PSE
or melanoma screening itself, we can only speculate
regarding the benefit of an earlier, nondiagnostic physi-
cian visit. It is possible that, at an earlier visit, the physi-
cian told the patient to follow a particular mole that
subsequently changed or that the physician made note of
a mole of concern that was not suspicious enough to war-
rant biopsy. Whether PSE overcomes patient delay in
seeking medical attention for a suspicious lesion because
of a lack of awareness or lower performance of SSE, or
results in the detection of intrinsically less aggressive,
slow-growing tumors (length bias) warrants further study.
Likewise, it is not clear why men aged >60 years,
compared with younger men and all women in our study,
Table 4. (Continued)
Variable/Subgroup Response No. of
Patients
OR for Tumor
£1 mm (95% CI)
Men aged >60 y
No 59 Ref
Yes 100 4.09 (1.88-8.89)
Women aged >60 y
No 31 Ref
Yes 31 1.40 (0.43-4.53)
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference group; SSE, skin self-examination.
a Variables pertain to the year before melanoma diagnosis.
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reported nearly 1.5 to 3 more PSEs in the year before diag-
nosis. One study demonstrated that men aged 50 years
with a personal history of skin cancer were more likely to
seek skin screening compared with women and younger
men, although women were more likely to seek medical
attention because of a particular lesion concerning for skin
cancer.41 However, low rates of prior skin cancer and mela-
noma in our study cohort (6% and 5%, respectively) do not
support this explanation for increased PSEs in older men.
Other possibilities include patient or physician recognition
of higher melanoma risk, prompting of the physician by the
patient or his spouse/partner in requesting a skin examina-
tion, or more suspicious but noncancerous lesions triggering
routine PSE. Although the reasons for the stronger associa-
tion of thinner tumors with PSE in older men do not appear
to be a greater number of physician visits or differences in
anatomic location, these issues, as well as a more detailed
analysis of the role of physician detection in finding earlier
nodular and desmoplastic subtypes, should be explored in
future studies.
Study limitations include reliance on self-reports of
health behaviors (SSE) and practices (health care use and
PSE) and recall accuracy. Although all patients completed
surveys within 3 months of diagnosis, potential over-report-
ing of health prevention practices is a possibility. Because
the recall period for SSE and PSE practices extended up to
15 months (12 months before diagnosis coupled with a sur-
vey period of up to 3 months), there was likely some mis-
classification of these measures. In typical studies in which
exposure is ascertained after diagnosis, differential misclassi-
fication of exposure (recall bias) can result in either exagger-
ation or dilution of the estimated association and is an
important concern. However, in our study, all individuals
had been diagnosed withmelanoma, and the only difference
was thickness, which makes it more likely that the main
mechanism of misclassification would be nondifferential
and, thus, would have underestimated the association. In
addition, patient perception of who discovered the mela-
noma may vary, particularly if the patient notices a suspi-
cious lesion but reports that the physician who performed
the diagnostic biopsy discovered it. Strengths include the ge-
ographic diversity of the data collected, low rates of case re-
fusal, short interval between diagnosis and completion of
the survey, and contemporaneous clinician validation of ne-
vus count and presence of clinical atypical nevi.
Because 72% of fatal melanomas are>1 mm thick at
diagnosis,30 reducing the burden of melanoma >1 mm
should be a goal to decrease mortality. To our knowledge,
our study is the first to assess the effects of SSE and PSE by
age and sex and to define the strong effect that physician
screening has on the detection of thinner melanoma in
older men. Our findings suggest that regular SSE and PSE
potentially can surmount the higher mortality associated
with this subgroup. Although both partial and whole-body
examinations appear to be effective in older men, full-body
PSE is preferable for the detection of melanoma in less visi-
ble but common sites (eg, back and scalp) that may be
missed with the examination of a particular lesion.
Facilitating the performance of PSE in clinical practice
requires overcoming both patient and physician barriers (eg,
time constraints, competing comorbidities, and patient
embarrassment).42 Routine PSE can be accomplished
through enhanced physician training, physician awareness
of higher risk for melanoma in the patient, and patient
request for a full-body skin examination. Because so many
individuals at risk of melanoma routinely consult physi-
cians,43 improving physician training in full-body skin ex-
amination and increasing patient self-advocacy in requesting
PSE are realistic strategies to improve early detection.
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